Chen Zheng, Liu Huiling, Wang Hong, Wu Changshun, Feng Hong, Han Junqing
Cancer Center, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Department of Head and Neck Radiotherapy, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
J Cancer Res Ther. 2018;14(4):815-819. doi: 10.4103/jcrt.JCRT_991_17.
The tumor inhibition by magnetic fields (MFs) has been reported in many in vivo and in vitro studies, while clinical trials have been rare. This report aimed to evaluate the improvement of survival and general symptoms in advanced cancer patients treated with MFs.
In this study, we investigated 21 patients with advanced gastric cancer (AGC) treated with 420 r/min, 0.4-T low-frequency rotary MFs. The treatment area encompassed the primary tumor sites, metastatic sites, and metastatic lymph nodes. In addition, the patients were treated 2 h per day, 5 days per week for 6-12 weeks. The toxicity pilot human study was approved by the competent ethical committee. Toxicity and side effects were assessed according to the WHO criteria. The changes of general symptoms were analyzed during low-frequency rotary MFs treatment and 2 weeks after the end of therapy. Electrocardiogram, chest X-ray, physical examination, blood cell count and complete blood chemistry, biochemical, and kidney function tests were performed before and after the end of the treatment. All 21 patients were followed up by outpatient service or telephone interview.
Our results demonstrated that low-frequency rotary MFs improved abdominal pain in 9/21 (42.9%), nausea/vomiting in 4/21 (19.0%), weight loss in 11/21 (52.4%), ongoing blood loss in 2/21 (9.5%), physical strength in 5/21 (23.8%), and sleep quality in 4/21 (19.0%) patients. No severe toxicity and side effect were observed in our trial. The median survival time was 8.0 months (95% confidence interval, 5.190-10.810). The 1-year survival rate was 25.8%.
Low-frequency rotary MFs may prolong survival and improve general symptom of AGC patients, as an effective, well-tolerated, and safe treatment choice.
许多体内和体外研究均报道了磁场（MFs）对肿瘤的抑制作用，但临床试验却很少。本报告旨在评估接受MFs治疗的晚期癌症患者的生存期改善情况和一般症状。
在本研究中，我们调查了21例接受420转/分钟、0.4特斯拉低频旋转磁场治疗的晚期胃癌（AGC）患者。治疗区域包括原发肿瘤部位、转移部位和转移淋巴结。此外，患者每天治疗2小时，每周5天，共治疗6至12周。毒性预试验人体研究已获得主管伦理委员会的批准。根据世界卫生组织标准评估毒性和副作用。在低频旋转磁场治疗期间及治疗结束后2周分析一般症状的变化。在治疗结束前后进行心电图、胸部X线、体格检查、血细胞计数及全血化学、生化和肾功能检查。所有21例患者均通过门诊服务或电话随访。
我们的结果表明，低频旋转磁场改善了21例患者中9例（42.9%）的腹痛、4例（19.0%）的恶心/呕吐、11例（52.4%）的体重减轻、2例（9.5%）的持续失血、5例（23.8%）的体力以及4例（19.0%）的睡眠质量。在我们的试验中未观察到严重的毒性和副作用。中位生存时间为8.0个月（95%置信区间，5.190 - 10.810）。1年生存率为25.8%。
低频旋转磁场可能延长AGC患者的生存期并改善其一般症状，是一种有效、耐受性良好且安全的治疗选择。
